Many of today's equestrian businesses still use, in terms of management and training, methods based on insights from the last century. If we, as a profession, want to continue supporting equestrian sports in a positive way over the next decade, it is essential to revise these methods and provide horse owners with sufficient practical tools to do so.
Nutrition plays a vital role within managing horse welfare; a proper ration is essential. Although
HorStem is the first registered veterinary medicine based on mesenchymal stem cells obtained from the umbilical cord of horses. Stem cells reduce lameness in horses with mild to moderate degenerative joint disease (OA).
It is a ready-to-use, sterile, injectable suspension for intra-articular use in horses. Each vial contains 15 million active stem cells, more than enough to achieve the minimum effective dose in the joint regardless of the degree of inflammation or the patient's immune system status.
The mechanism of action of HorStem is illustrated in the figure on the right. Mesenchymal stem cells are activated in the synovium by inflammatory cytokines. In response, they secrete anti-inflammatory cytokines such as Prostaglandin E2 (PGE2).
While PGE2 is primarily known for its pro-inflammatory effects, it also plays a crucial role in regulating inflammation. It is one of the major immunomodulatory cytokines in the body.
When applied to horses with OA, HorStem inhibits T-cell proliferation, reduces the production of pro-inflammatory cytokines like TNF-alpha, and decreases the presence of matrix metalloproteinases (MMPs) that contribute to the breakdown of cartilage's extracellular matrix. Studies have shown that these effects are mediated by PGE2. (1)
Moreover, umbilical cord-derived mesenchymal stem cells stimulate the production of anti-inflammatory cytokines such as IL-4, IL-5, IL-10, and TGF-beta. As the inflammatory response ceases
Expansion adds new countries to Grovet's existing PulseVet distribution coverage and enables launch of the TRUFORMA® equine platform in Europe
ANN ARBOR, MI / ACCESSWIRE / October 3, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the expansion of its distribution partnership in Europe with Grovet, a leading equine-focused veterinary distributor.
The terms of the updated agreement offer Grovet equine distribution rights for Zomedica's equine PulseVet® and TRUFORMA product platforms throughout most of Europe. Grovet will exclusively distribute these equine products in 27 countries, including Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary,
